Tomer A, Hanson S R, Harker L A
Department of Medicine, Emory University School of Medicine, Atlanta, GA 30322.
J Lab Clin Med. 1991 Dec;118(6):546-54.
Measurements of platelet survival and turnover in severe thrombocytopenia have proven difficult to perform and interpret. To examine the mechanisms by which platelet life span is reduced and to determine the capacity of platelet kinetic studies to discriminate between increased platelet destruction and impaired platelet production in patients with moderate to severe thrombocytopenia, we developed a modified method for labeling autologous platelets with indium-111-oxine (which increases labeling efficiency, reduces the required volumes of blood, and decreases platelet manipulation in vitro) and conducted a prospective study in 26 patients with thrombocytopenia. Seventeen patients had megakaryocytic hypoplasia (platelet count 51 x 10(9)/L, range 10 x 10(9)/L to 150 x 10(9)/L; reduced megakaryocytes in marrow smears and biopsy sample), nine patients had clinical idiopathic thrombocytopenic purpura (ITP) (platelet count 79 x 10(9)/L, range 19 x 10(9)/L to 150 x 10(9)/L; normal to increased megakaryocytes with otherwise normal marrow, and seven patients displayed the presence of autoantibodies directed against platelet glycoproteins IIb-IIIa or Ib). Although platelet life span was shortened in all patients, the average platelet survival time measured in patients with megakaryocyte hypoplasia was substantially longer than that measured in patients with ITP. Only platelet survival times measured in patients with megakaryocyte hypoplasia were predicted by the degree of thrombocytopenia. Platelet turnover was reduced in all patients with megakaryocytic hypoplasia but was variable in the patients with ITP. Platelet turnover values correlated with circulating platelet counts in patients with marrow hypoplasia but not in the patients with ITP.(ABSTRACT TRUNCATED AT 250 WORDS)
事实证明,在严重血小板减少症中测量血小板存活和更新情况既难以实施,也难以解读。为了研究血小板寿命缩短的机制,并确定血小板动力学研究在区分中度至重度血小板减少症患者中血小板破坏增加和血小板生成受损方面的能力,我们开发了一种改良方法,用铟 - 111 - 奥克辛标记自体血小板(该方法提高了标记效率,减少了所需血量,并减少了体外对血小板的操作),并对26例血小板减少症患者进行了一项前瞻性研究。17例患者患有巨核细胞发育不全(血小板计数51×10⁹/L,范围为10×10⁹/L至150×10⁹/L;骨髓涂片和活检样本中巨核细胞减少),9例患者患有临床特发性血小板减少性紫癜(ITP)(血小板计数79×10⁹/L,范围为19×10⁹/L至150×10⁹/L;巨核细胞正常至增多,骨髓其他方面正常,7例患者显示存在针对血小板糖蛋白IIb - IIIa或Ib的自身抗体)。尽管所有患者的血小板寿命均缩短,但巨核细胞发育不全患者测得的平均血小板存活时间明显长于ITP患者。只有巨核细胞发育不全患者测得的血小板存活时间可由血小板减少程度预测。所有巨核细胞发育不全患者的血小板更新均减少,但ITP患者的血小板更新情况各不相同。骨髓发育不全患者的血小板更新值与循环血小板计数相关,而ITP患者则不然。(摘要截短于250字)